Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 65 | 3,602 | 37% |
| 2020 | 56 | 3,163 | 40% |
| 2021 | 65 | 3,463 | 43% |
| 2022 | 63 | 3,283 | 46% |
| 2023 | 61 | 3,022 | 50% |
| 2024 | 61 | 2,895 | 54% |
| 2025 from claims | – | 2,909 2,670–3,078 | 54% |
| 2026 forecast | – | 2,946 2,592–3,400 | 54% |
| 2027 forecast | – | 2,948 2,520–3,513 | 55% |
| 2028 forecast | – | 2,949 2,460–3,610 | 56% |
| 2029 forecast | – | 2,949 2,408–3,698 | 57% |
| 2030 forecast | – | 2,948 2,361–3,777 | 57% |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 35% of the cases CMS names in Washington; 36 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 47% inpatient hospital, 53% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~2,900 | ~1,400 | ~1,500 |
| 2027 · ~2,900 | ~1,400 | ~1,500 |
| 2028 · ~2,900 | ~1,400 | ~1,500 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 52% (53% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 239 | 12,086−4.4%/yr | −4.4%/yr | 3.7 | 4% | 12,400 in 2030+0.5%/yr |
| Arizona | 85 | 4,095−2.6%/yr | −2.6%/yr | 5.7 | 26% | 4,390 in 2030+1.2%/yr |
| Colorado | 38 | 1,903−1.6%/yr | −1.6%/yr | 4.1 | 0% | 2,210 in 2030+2.5%/yr |
| Oregon | 32 | 1,588−2.2%/yr | −2.2%/yr | 4.0 | 3% | 1,810 in 2030+2.2%/yr |
| Nevada | 21 | 1,111−3%/yr | −3%/yr | 4.0 | 2% | 1,240 in 2030+1.8%/yr |
| Utah | 22 | 921−2.8%/yr | −2.8%/yr | 4.4 | 0% | 900 in 2030−0.4%/yr |
| Montana | 15 | 883+1.5%/yr | +1.5%/yr | 4.7 | 0% | 880 in 20300%/yr |
| Idaho | 16 | 883+3.2%/yr | +3.2%/yr | 4.5 | 0% | 1,260 in 2030+6.1%/yr |
| New Mexico | 11 | 618−2.3%/yr | −2.3%/yr | 2.8 | 0% | 670 in 2030+1.3%/yr |
| Alaska | 6 | 384−0.5%/yr | −0.5%/yr | 3.2 | 26% | 440 in 2030+2.2%/yr |
| Wyoming | 3 | 122+2.7%/yr | +2.7%/yr | 1.1 | 0% | 190 in 2030+7.7%/yr |
| Hawaii | 3 | 114−16%/yr | −16%/yr | 0.9 | 0% | 130 in 2030+2.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| EP ablation | 49 | 2,678+2.4%/yr | +2.4%/yr | 2.91.0× | 0% | 4,000 in 2030+6.9%/yr |
| LAA occlusion & loop recorders | 46 | 2,007+11%/yr | +11%/yr | 2.30.8× | 2% | 3,420 in 2030+9.3%/yr |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
Boston Scientific leads with 45% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 8 companies reported engagement with Washington’s surgeons worth $68K in consulting, speaking, meals and travel tied to these products, about $1,118 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.